Literature DB >> 33506012

Insulin Receptor Substrate p53 Ameliorates High-Glucose-Induced Activation of NF-κB and Impaired Mobility of HUVECs.

Fen Liu1, Yubin Chen2, Shi Zhao1, Mei Li1, Fanyan Luo2, Can-E Tang1.   

Abstract

Diabetes-related macrovascular and microvascular complications lead to poor prognosis. Insulin receptor substrate p53 (IRSp53) is known to act as a substrate for the insulin receptor tyrosine kinase, but its role in endothelial dysfunction remains unclear. Human umbilical vein endothelial cells (HUVECs) treated with D-glucose at different concentrations and a streptozocin-induced rat diabetes mellitus (DM) model were used to investigate the effects of hyperglycemia on the expression levels of IRSp53 and galectin-3 (gal-3) and the inflammatory state and mobility of HUVECs. Thereafter, IRSp53-overexpressing HUVECs and IRSp53-knockdown HUVECs were established using IRSp53-overexpressing lentivirus or IRSp53-siRNA to explore the role of IRSp53 in the HUVEC inflammatory state and HUVEC mobility. D-glucose at high concentration (HG) and hyperglycemia were found to induce downregulation of IRSp53 and upregulation of gal-3 in vitro and in vivo. Treatment with HG resulted in activation of NF-κB in HUVECs and impaired HUVEC mobility. Insulin restored HG-induced changes in the expression levels of IRSp53 and gal-3 in HUVECs and protected the cells from NF-κB activation and impaired mobility. Overexpression of IRSp53 inhibited the activation of NF-κB in HUVECs and strengthened HUVEC migration. Knockdown of IRSp53 facilitated the activation of NF-κB in HUVECs and decreased HUVEC migration. However, neither overexpression nor knockdown of IRSp53 altered the effects of insulin on HG-induced detrimental changes in HUVECs. HG and hyperglycemia resulted in downregulation of IRSp53 in vitro and in vivo. IRSp53 is concluded to inhibit the activation of NF-κB in HUVECs and to strengthen HUVEC migration.
Copyright © 2021 Fen Liu et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33506012      PMCID: PMC7806382          DOI: 10.1155/2021/3210586

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  34 in total

Review 1.  Natural history and histological classification of atherosclerotic lesions: an update.

Authors:  H C Stary
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-05       Impact factor: 8.311

2.  IRSp53/Eps8 complex is important for positive regulation of Rac and cancer cell motility/invasiveness.

Authors:  Yosuke Funato; Takeshi Terabayashi; Naoko Suenaga; Motoharu Seiki; Tadaomi Takenawa; Hiroaki Miki
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

Review 3.  Oxidative stress and diabetic complications.

Authors:  Ferdinando Giacco; Michael Brownlee
Journal:  Circ Res       Date:  2010-10-29       Impact factor: 17.367

4.  Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate IRS1-4.

Authors:  R Böhni; J Riesgo-Escovar; S Oldham; W Brogiolo; H Stocker; B F Andruss; K Beckingham; E Hafen
Journal:  Cell       Date:  1999-06-25       Impact factor: 41.582

5.  Hematopoietic-Derived Galectin-3 Causes Cellular and Systemic Insulin Resistance.

Authors:  Pingping Li; Shuainan Liu; Min Lu; Gautum Bandyopadhyay; Dayoung Oh; Takeshi Imamura; Andrew M F Johnson; Dorothy Sears; Zhufang Shen; Bing Cui; Lijuan Kong; Shaocong Hou; Xiao Liang; Salvatore Iovino; Steven M Watkins; Wei Ying; Olivia Osborn; Joshua Wollam; Martin Brenner; Jerrold M Olefsky
Journal:  Cell       Date:  2016-11-03       Impact factor: 41.582

Review 6.  Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.

Authors:  R A DeFronzo; E Ferrannini
Journal:  Diabetes Care       Date:  1991-03       Impact factor: 19.112

7.  The interplay between Eps8 and IRSp53 contributes to Src-mediated transformation.

Authors:  P-S Liu; T-H Jong; M-C Maa; T-H Leu
Journal:  Oncogene       Date:  2010-04-26       Impact factor: 9.867

8.  Galectin-3 reduces the severity of pneumococcal pneumonia by augmenting neutrophil function.

Authors:  Sarah L Farnworth; Neil C Henderson; Alison C Mackinnon; Kirsten M Atkinson; Tom Wilkinson; Kevin Dhaliwal; Katsutoshi Hayashi; A John Simpson; Adriano G Rossi; Christopher Haslett; Tariq Sethi
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

9.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

Authors:  Sarah Wild; Gojka Roglic; Anders Green; Richard Sicree; Hilary King
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

10.  De novo mutations in schizophrenia implicate synaptic networks.

Authors:  Menachem Fromer; Andrew J Pocklington; David H Kavanagh; Hywel J Williams; Sarah Dwyer; Padhraig Gormley; Lyudmila Georgieva; Elliott Rees; Priit Palta; Douglas M Ruderfer; Noa Carrera; Isla Humphreys; Jessica S Johnson; Panos Roussos; Douglas D Barker; Eric Banks; Vihra Milanova; Seth G Grant; Eilis Hannon; Samuel A Rose; Kimberly Chambert; Milind Mahajan; Edward M Scolnick; Jennifer L Moran; George Kirov; Aarno Palotie; Steven A McCarroll; Peter Holmans; Pamela Sklar; Michael J Owen; Shaun M Purcell; Michael C O'Donovan
Journal:  Nature       Date:  2014-01-22       Impact factor: 49.962

View more
  1 in total

Review 1.  Recent advances in molecular biology of metabolic syndrome pathophysiology: endothelial dysfunction as a potential therapeutic target.

Authors:  Basheer Abdullah Marzoog
Journal:  J Diabetes Metab Disord       Date:  2022-08-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.